Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 15;9(3):e002096. doi: 10.1136/jitc-2020-002096

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Tumor growth in survivors following rechallenge with 4T1. Tumor resected mice that survived to day 120 after treatment with α-galactosylceramide (α-GalCer)-loaded dendritic cells (DCs), vesicular stomatitis virus (VSV), combination of VSV and α-GalCer-loaded DCs (figure 2) were rechallenged in the contralateral mammary fat pad with 2×0⁵ 4T1 cells. (A) Tumor volume was compared with tumors grown in naïve mice (n=4–7 per group, except n=1 for VSV group). (B) Metastatic burden at day 25 was compared with naïve tumor-bearing mice (n=4–7 per group, except n=1 for VSV group). *p<0.05 compared with naïve control.